Radicava samþykkt sem lyf við MND. Fyrsta í 22 ár.
- Nánar
- Búin til þann 07 Maí 2017
The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (MND/ALS), commonly referred to as Lou Gehrig’s disease.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm557102.htm
